Evidence map›Paper›PMID 24072676›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2013

A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions.

B Karthik Grandhi, Arvind Thakkar, Jeffrey Wang, Sunil Prabhu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Pancreatic Cancer: Recent Advances in Nanoformulation-Based Therapies.Critical reviews in therapeutic drug carrier systems · 2019
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Convergence of nanotechnology and cancer prevention: are we there yet?Cancer prevention research (Philadelphia, Pa.) · 2014
    Review
  16. Article
  17. Big punches come in nanosizes for chemoprevention.Cancer prevention research (Philadelphia, Pa.) · 2013
    Article
  18. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

B Karthik Grandhi *Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, 309 E 2 Street, Pomona, CA 91766, USA.
Arvind Thakkar *Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, 309 E 2 Street, Pomona, CA 91766, USA.
Jeffrey WangDepartment of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, 309 E 2 Street, Pomona, CA 91766, USA.
Sunil PrabhuDepartment of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, 309 E 2 Street, Pomona, CA 91766, USA.
Western University of Health Sciences · US

Funding

Chemoprevention of pancreatic cancer using a combinatorial nano-drug systemR03CA153812 · NCI · WESTERN UNIVERSITY OF HEALTH SCIENCES · PI PRABHU, SUNIL · 2011 to 2012
$149k
NCI NIH HHS 1R03CA153812-01A1NCI NIH HHS R03 CA153812
6 · The paper itself

Abstract

Pancreatic cancer is a deadly disease killing 37,000 Americans each year. Despite two decades of research on treatment options, the chances of survival are still less than 5% upon diagnosis. Recently, chemopreventive strategies have gained considerable attention as an alternative to treatment. We have previously shown significant in vitro chemopreventive effects with low-dose combinations of aspirin, curcumin, and sulforaphane (ACS) on pancreatic cancer cell lines. Here, we report the results of 24-week chemopreventive study with the oral administration of ACS combinations on the N-nitrosobis (2-oxopropyl) amine (BOP)-treated Syrian golden hamster model to suppress the progression of pancreatic intraepithelial neoplasms (PanIN) using unmodified (free drug) combinations of ACS, and nanoencapsulated (solid lipid nanoparticles; SLN) combinations of aspirin, curcumin, and free sulforaphane. The use of three different doses (low, medium, and high) of unmodified ACS combinations exhibited reduction in tumor incidence by 18%, 50%, and 68.7% respectively; whereas the modified nanoencapsulated ACS regimens reduced tumor incidence by 33%, 67%, and 75%, respectively, at 10 times lower dose compared with the free drug combinations. Similarly, although the unmodified free ACS showed a notable reduction in cell proliferation, the SLN encapsulated ACS regimens showed significant reduction in cell proliferation at 6.3%, 58.6%, and 72.8% as evidenced by proliferating cell nuclear antigen expression. Cell apoptotic indices were also upregulated by 1.5, 2.8, and 3.2 times, respectively, compared with BOP control. These studies provide a proof-of-concept for the use of an oral, low-dose, nanotechnology-based combinatorial regimen for the long-term chemoprevention of pancreatic cancer.

Indexed as

Drug Delivery SystemsAdenocarcinomaAdministration, OralAnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsApoptosisAspirinCarcinogensCell Line, TumorCricetinaeCurcuminDisease Models, AnimalDisease ProgressionImmunohistochemistryIn Situ Nick-End LabelingAntineoplastic AgentsAspirinCarcinogensCurcuminIsothiocyanatesLipidsNitrosaminesnitrosobis(2-oxopropyl)amineProliferating Cell Nuclear AntigensulforaphaneSulfoxides

Identifiers

PMID24072676
PMCPMC3791209
OpenAlexW2016390566

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.